Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 59.71B |
| Revenue (ttm) | 14.20B |
| Net Income (ttm) | 4.41B |
| Shares Out | 107.02M |
| EPS (ttm) | 38.34 |
| PE Ratio | 14.55 |
| Forward PE | 13.40 |
| Dividend | $0.88 (0.16%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 838,464 |
| Open | 569.05 |
| Previous Close | 571.06 |
| Day's Range | 554.95 - 573.61 |
| 52-Week Range | 525.99 - 1,211.20 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 976.12 (+74.96%) |
| Earnings Date | Apr 29, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $976.12, which is an increase of 74.96% from the latest price.
News
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron's Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent continues ...
RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO
Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.
Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share
Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday...
Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Inves...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to i...
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmace...
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most disti...
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fe...
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman
REGN Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline SAN FRANCISCO, CA / ACCESS Newswire / March 5, 2025 / Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is facing h...